We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. According to findings in a recently published study, the ...
Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain and Modic Type 1 changes PP353 has the potential to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers found sick-listed low back pain patients ...
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Table 1. Size and proportion of Modic Type 1 (M1), Type 2 (M2) and Type 3 (M3) at baseline and follow-up, and scores of low back symptoms at baseline and follow-up ...
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is developing PP353, a potentially curative, opioid-sparing ...
(MENAFN- GlobeNewsWire - Nasdaq) ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet's eClinicalMedicine London, UK, 19 March 2026 - Persica ...
London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results